Topas Therapeutics
Topas Therapeutics develops antigen-specific nanoparticle technology designed to establish immune tolerance in patients with autoimmune and immune-mediated diseases. Its proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells to induce regulatory T cells and reduce inflammatory responses. The company is currently advancing its lead candidate, TPM502, into Phase 2b clinical trials for the treatment of celiac disease.
Biotechnology
Healthcare
Life Sciences
Nanotechnology
Funding summary
- Total raised
- €40.0M
- Funding rounds
- 2
Investors in Topas Therapeutics
Investors on record for Topas Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Topas Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors